Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of TEG002 Infusion in Relapsed/Refractory Multiple Myeloma Patients

NCT04688853 is registered in ClinicalTrials.gov with Gadeta B.V. as lead sponsor.

NCT NCT04688853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04688853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of TEG002 Infusion in Relapsed/Refractory Multiple Myeloma Patients
Lead sponsor
Gadeta B.V.
Phase
Phase 1
Overall status
Unknown status
Start date
May 13, 2021
Completion date
July 30, 2024
Enrollment
26 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, multiple myeloma in relapse, multiple myeloma, refractory